StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
6-factor scoring with sector-relative rank. Updated daily.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-13 | $0.77 | $0.81 | +5.97% | 0.3M |
| 05-14 | $0.82 | $0.89 | +8.29% | 0.6M |
| 05-15 | $0.86 | $0.91 | +5.96% | 0.5M |
| 05-18 | $0.91 | $0.84 | -7.80% | 0.4M |
| 05-19 | $0.86 | $0.88 | +2.12% | 0.3M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA). Geographically, it derives maximum revenue from the United States, followed by Germany, and other international.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $10.11M | $40.93M | $29.57M | $19.48M |
Operating Income | $-3.16M | $-14.40M | $-11.63M | $-8.11M |
Net Income | $-3.01M | $-15.57M | $-11.76M | $-4.63M |
EPS (Diluted) | $-0.07 | $-0.37 | $-0.28 | $-0.20 |
Total Assets | $36.75M | $38.64M | $34.08M | $38.67M |
Total Liabilities | $27.75M | $27.23M | $19.45M | $21.06M |
Cash & Equivalents | $11.40M | $14.13M | $12.55M | $14.24M |
Free Cash Flow OCF − CapEx | $-2.53M | $-16.25M | $-16.35M | $-13.47M |
Shares Outstanding | 38.57M | 38.47M | 38.43M | 37.78M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.